The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling

Oncogene

Volumn 34, Issue 9, 2015, Pages 1105-1115

  Huang, Z ^a   Choi, B K ^a   Mujoo, K ^a   Fan, X ^a   Fa, M ^a   Mukherjee, S ^a   Owiti, N ^a   Zhang, N ^a   An, Z ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR; SHORT HAIRPIN RNA; UBIQUITIN PROTEIN LIGASE NEDD4; ERBB3 PROTEIN, HUMAN; ESCRT PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; NRG1 PROTEIN, HUMAN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; BINDING SITE; CANCER TRANSPLANTATION; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENE SILENCING; HEK293 CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETULUS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUREGULIN-1; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84928302682     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.56     Document Type: Article

References (58)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.
3. Menendez JA, Lupu R. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res 2007;9:111.
4. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010;107:7692-7697.
5. Carraway KL, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
6. Vijapurkar U, Cheng K, Koland JG. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J Biol Chem 1998;273:20996-21002.
7. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994;13:2831-2841.
8. Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-3558.
9. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998;333:757-763.
10. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413-448.
11. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
12. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003;100:8933-8938.
13. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
14. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S et al. Oncogenic ERBB3 Mutations in Human Cancers. Cancer Cell 2013;23:603-617.
15. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-280.
16. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010;21(Suppl 7): vii36-vii40.
17. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
18. Hsieh A C, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-457.
19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
20. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441.
21. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009;2: ra31.
22. Schoeberl B, Faber AC, Li D, Liang M-C, Crosby K, Onsum M et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-2494.
23. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D et al. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies. Cancer Cell 2011;20:472-486.
24. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res 2003;5:8-15.
25. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
26. Ardley HC, Robinson PA. E3 ubiquitin ligases. Essays Biochem 2005;41:15-30.
27. Carraway KL. E3 ubiquitin ligases in ErbB receptor quantity control. Semin Cell Dev Biol 2010;21:936-943.
28. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001;2:294-307.
29. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperonedependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 2002;99:12847-12852.
30. Omerovic J, Santangelo L, Puggioni EM-R, Marrocco J, Dall'Armi C, Palumbo C et al. The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 2007;21:2849-2862.
31. Zeng F, Xu J, Harris RC. Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J 2009;23:1935-1945.
32. Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway KL. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci USA 2002;99:2866-2871.
33. Qiu X-B, Goldberg AL. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci USA 2002;99:14843-14848.
34. Maspero E, Mari S, Valentini E, Musacchio A, Fish A, Pasqualato S et al. Structure of the HECT: ubiquitin complex and its role in ubiquitin chain elongation. EMBO Rep 2011;12:342-349.
35. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009;10:398-409.
36. Persaud A, Alberts P, Hayes M, Guettler S, Clarke I, Sicheri F et al. Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J 2011;30:3259-3273.
37. Ingham RJ, Gish G, Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 2004;23:1972-1984.
38. Huang X, Poy F, Zhang R, Joachimiak A, Sudol M, Eck MJ. letters Structure of a WW domain containing fragment of dystrophin in complex with β-dystroglycan. Nature 2000. 7634-8.
39. Choi B-K, Cai X, Yuan B, Huang Z, Fan X, Deng H et al. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways. Protein Cell 2012;3:781-789.
40. Choi B-K, Fan X, Deng H, Zhang N, An Z. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Med 2012;1:28-38.
41. Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius K-J, Jarvius J et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995-1000.
42. Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z et al. Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol 2009;5:333.
43. Waterman H, Alroy I, Strano S, Seger R, Yarden Y. The C-terminus of the kinasedefective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 1999;18:3348-3358.
44. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998;12:3663-3674.
45. Sweeney C, Carraway KL. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer 2004;90:289-293.
46. Feng S-M, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K et al. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol 2009;29:892-906.
47. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A. The Grb10/Nedd4 Complex Regulates Ligand-Induced Ubiquitination and Stability of the Insulin-Like Growth Factor I Receptor The Grb10/Nedd4 Complex Regulates Ligand-Induced Ubiquitination and Stability of the Insulin-Like Growth Factor I Receptor. Mol Cell Biol 2003;23:3363-3372.
48. Huang Q, Szebenyi DME. Structural basis for the interaction between the growth factor-binding protein GRB10 and the E3 ubiquitin ligase NEDD4. J Biol Chem 2010;285:42130-42139.
49. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
50. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S et al. Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation. Cell 2003;112:779-791.
51. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 2004;64:7226-7230.
52. Bouyain S, Leahy D. Structure-based mutagenesis of the substrate recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3. Protein Sci 2007;16:654-661.
53. Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012;106:6-13.
54. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011;108:5021-5026.
55. Chaib H, Cockrell EK, Rubin MA, Macoska JA. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 2001.; 3:43-52.
56. Koumakpayi IH, Diallo J-S, Le Page C, Lessard L, Gleave M, Bégin LR et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 2006;12:2730-2737.
57. Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006;27:1054-1067.
58. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997.; 3:21-30.